Estimating nuclear scanning capacity requirements for patients with suspected cardiac transthyretin amyloidosis

ESC Heart Fail. 2023 Apr;10(2):1492-1496. doi: 10.1002/ehf2.14315. Epub 2023 Feb 21.

Authors

Vincenzo C Leo¹, Syed Kazmi², Jack Brownrigg¹, Marzieh Araghi¹, Harpreet S Sarna¹, Pierpaolo Pellicori³, Joe Cuthbert⁴, John G F Cleland³, Andrew L Clark²

Affiliations

¹ Pfizer Ltd, Walton Oaks, Dorking Rd, Tadworth, KT20 7NS, UK.
² Hull University Teaching Hospitals Trust, Castle Hill Hospital, Castle Rd, Cottingham, HU16 5JQ, UK.
³ British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK, G12 8QQ.
⁴ Hull York Medical School Castle Hill Hospital, Castle Rd, Cottingham, Kingston upon Hull, HU16 5JQ, UK.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Amyloid Neuropathies, Familial* / diagnosis
Heart
Humans

Supplementary concepts

Amyloidosis, Hereditary, Transthyretin-Related